Literature DB >> 8027367

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.

J R Salisbury1, N T Rapson, J D Codd, M V Rogers, A B Nethersell.   

Abstract

AIM: To determine the antigen expression of CDw52 using Campath-1 antibodies in a series of non-Hodgkin's lymphomas (NHLs).
METHODS: Tissue sections of lymphoma were stained immunohistochemically using rat Campath-1G and humanised Campath-1H with avidin-biotin-peroxidase complex techniques. Fifty-two fresh frozen lymphomas and a further 26 paraffin wax embedded sections were studied.
RESULTS: Thirty-seven out of 41 B cell lymphomas were positive with Campath-1H in frozen sections (low grade, 24 of 24; high grade, 13 of 17) as were three out of five T cell lymphomas. Reed-Sternberg cells in six cases of Hodgkin's disease did not react. Eleven out of 16 high grade B cell lymphomas also stained positively with Campath-1G in paraffin wax sections as did five out of 10 T cell lymphomas.
CONCLUSIONS: The Campath-1 antibodies showed that CDw52 antigen expression was present in all cases of low grade B cell NHL examined. Immunohistochemical staining in high grade B cell NHL and in T cell NHL was variable. These findings may be relevant to patient selection when considering treatment with Campath-1 antibodies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027367      PMCID: PMC501933          DOI: 10.1136/jcp.47.4.313

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1.

Authors:  S H Smith; M H Brown; D Rowe; R E Callard; P C Beverley
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

2.  Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

Authors:  G Hale; M J Dyer; M R Clark; J M Phillips; R Marcus; L Riechmann; G Winter; H Waldmann
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

3.  Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections.

Authors:  S Poppema; H Hollema; L Visser; H Vos
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Updated Kiel classification for lymphomas.

Authors:  A G Stansfeld; J Diebold; H Noel; Y Kapanci; F Rilke; G Kelényi; C Sundstrom; K Lennert; J A van Unnik; O Mioduszewska
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

6.  Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies.

Authors:  Y Ishii; T Takami; H Yuasa; T Takei; K Kikuchi
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

7.  Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes.

Authors:  G Hale; T Hoang; T Prospero; S M Watt; H Waldmann
Journal:  Mol Biol Med       Date:  1983-10

8.  Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans.

Authors:  G Hale; D M Swirsky; F G Hayhoe; H Waldmann
Journal:  Mol Biol Med       Date:  1983-10

9.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

10.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

View more
  8 in total

Review 1.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 2.  Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.

Authors:  G A Pangalis; M N Dimopoulou; M K Angelopoulou; C Tsekouras; T P Vassilakopoulos; G Vaiopoulos; M P Siakantaris
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 3.  Antibody therapy for chronic lymphocytic leukemia.

Authors:  Beth A Christian; Thomas S Lin
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

4.  Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Authors:  Gheath Alatrash; Maher Albitar; Susan O'Brien; Xuemei Wang; Taghi Manshouri; Stefan Faderl; Alessandra Ferrajoli; Jan Burger; Guillermo Garcia-Manero; Hagop M Kantarjian; Susan Lerner; Michael J Keating; William G Wierda
Journal:  Br J Haematol       Date:  2009-11-06       Impact factor: 6.998

Review 5.  [Treatment of hematological malignancies with monoclonal antibodies].

Authors:  G Held; J Schubert; M Pfreundschuh
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

6.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.

Authors:  Ajay K Gopal; John M Pagel; Jonathan R Fromm; Shani Wilbur; Oliver W Press
Journal:  Blood       Date:  2009-03-30       Impact factor: 22.113

7.  Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.

Authors:  Seok Jin Kim; Kihyun Kim; Yong Park; Byung Soo Kim; Jooryung Huh; Young Hae Ko; Keunchil Park; Cheolwon Suh; Won Seog Kim
Journal:  Invest New Drugs       Date:  2010-08-24       Impact factor: 3.651

8.  Richter's syndrome: a novel presentation.

Authors:  E F Smyth; R J V Bartlett; M L Shields; T J White; C Wengraf
Journal:  Ulster Med J       Date:  2003-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.